Hanley Conor sold $144K of KMTS

Hanley Conor sold 5,694 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $25.25 ($0.14M total) on 2026-09-08.

Original reporting
SEC EDGAR · Hanley Conor
Published Sep 11, 2026, 12:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The transaction is modest and unlikely to move the stock significantly, but it provides transparency for investors.

02

Market read

Provides a fresh data point for investors monitoring insider activity; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Sep 10, 2026

Background

SEC Form 4 filings disclose insider transactions; this filing reports a director's sale of KMTS shares.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Director Conor Hanley sold 5,694 shares of KMTS for $143,778, reducing his holding to 6,272 shares.

Expected impact

Potential short-term price pressure of 0.5‑1% if market reacts.

Evidence & confidence

A $144K sale by a director is a routine liquidity event; not material enough to drive a large move.

Market effects

Minimal impact on the medical device sector; insider activity is typical.

No regional effect; company trades on US exchanges.

Limited global relevance; only affects KMTS shareholders.

Counterpoint

The sale could be a strategic reallocation rather than a lack of confidence, suggesting no downside.

Key entities

  • KestrA Medical Technologies, Ltd.

    Medical device manufacturer listed on Nasdaq under ticker KMTS.

  • Conor Hanley

    Director of KMTS who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.